The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
Open accessAbstract
Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Secondary analyses of ACE inhibitors or ARBs in patients with heart failure or LVH show a lower incidence of new-onset AF.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [246]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472
Cited by
Sorted by citations
Items 801–819 of 819
Renal Sympathetic Denervation in Atrial Fibrillation Treatment
Uçar, M. (2024) · Cardiology and cardiovascular medicine. · doi:10.5772/intechopen.1006709
Non-antiarrhythmic Drugs with Antiarrhythmic Properties
Scridon, A., Ivănescu, A. C., & Halațiu, V.-B. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_8
AAD in Patients with Comorbidities
Sartiani, L., & Cerbai, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_14
The Geometry of Survival: Left Ventricular Mass Index's Prognostic Value in Coronary Surgery
Timur, B., Aksoy, R., Duman, Z. M., Çalışkan, R., Baş, K., Aydoğdu, C., & Koçoğulları, C. U. (2025) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/a-2637-0964
Du, W., Chen, X., Dong, Y., Chen, Q., Yadav, N., & Zhang, F. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm41914
Förstermann, U. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-42523-3.00018-x
第2回 不整脈薬物治療フォーラム 基調講演II心房細動に対するupstream治療の展望
山下, 武. (2005) · 心臓 · doi:10.11281/shinzo1969.37.9_805
Nazarzadeh, M., Pinho‐Gomes, A., Bidel, Z., Canoy, D., Dehghan, A., Smith Byrne, K., Bennett, D. A., Smith, G. D., & Rahimi, K. (2021) · Figshare · doi:10.6084/m9.figshare.14168440
Nazarzadeh, M., Pinho‐Gomes, A., Bidel, Z., Canoy, D., Dehghan, A., Smith Byrne, K., Bennett, D. A., Smith, G. D., & Rahimi, K. (2021) · Figshare · doi:10.6084/m9.figshare.14168434
Nazarzadeh, M., Pinho‐Gomes, A., Bidel, Z., Canoy, D., Dehghan, A., Smith Byrne, K., Bennett, D. A., Smith, G. D., & Rahimi, K. (2021) · Figshare · doi:10.6084/m9.figshare.14168443
Chen, Z., Tang, Y., Li, S., Pan, L., Wu, J., Liu, J., Ma, H., Wang, B., & Xie, K. (2026) · BMC Medicine · doi:10.1186/s12916-026-04691-5
Predicting atrial fibrillation after an acute coronary syndrome: insights from the BACS & BAMI study
Guerra, J. F. L., Capilla, Á. C., Bugeda, M. G., Kallmeyer, A., Cánovas, E., Tarin, M. N., Cristóbal, C., Huelmos, A. I., Landaluce, C. G., Chapel, J. A. E., et al. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02898-3
Gao, X., Zhang, Z., Chen, K., Jin, Y. Q., Chen, F., Zhang, J., Geng, L., Wang, K., Gao, C., Wang, L., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1827339
Selective Use of Nonselective Beta-Blockers
Genovese, D., Sgarito, G. A., Ruggiero, D., Perrotta, L., Francia, P., Santoro, F., & Mugnai, G. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2026.05.002
Zakeri, R., Camilli, M., D’Elia, E., Hulot, J., Iacoviello, M., Sisti, N., Țica, O., Tokmakova, M. P., den Eynde, J. V., Weerts, J., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag268
Alpaslan, E., Taş, S., Taş, Ü., Eyüboğlu, M., Duman, O. O., Dalgıç, O., Candan, L., & Özdemir, A. R. (2026) · International Journal of Hypertension · doi:10.1155/ijhy/2095472
Bi, S., Sun, Y., Zou, X., Ruan, X., & Zhu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1997453
Klassifikationen, Erkrankungsverläufe und Symptomatologie
CARLSSON, J., NEUZNER, J., & Erdogan, A. R. (2007) · Steinkopff eBooks · doi:10.1007/978-3-7985-1748-6_3
Role of Angiotensin-Receptor Blockers in the Prevention of Cardiovascular Risk: Clinical Guidelines
Filardi, P. P., Costanzo, P., Marzano, A., Cesarano, P., Gargiulo, P., Vassallo, E., Marciano, C., Losco, T., & Chiariello, M. (2007) · Springer eBooks · doi:10.1007/978-88-470-0636-2_52
Metadata
- Authors
- Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
- Affiliations
- Cornell University (US)
- Helsinki University Hospital (FI)
- Haukeland University Hospital (NO)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- University of Michigan (US)
- Oslo University Hospital (NO)
- University Hospital of Umeå (SE)
- Corresponding author
- Wachtell, Kristian
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 45
- Issue
- 5
- Pages
- 712-719
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2147918774
- Cited by
- 826
- References
- 27
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
- FWCI
- 64.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
